Germline TP53 splicing mutations have been described infrequently (42%) in the literature, however in a series of 40 patients and families identi®ed by our group in which there are germline TP53 mutations, seven aect splicing (18%). The low ®gure reported in the literature might re¯ect the method of mutation detection, which in many studies does not include all splice junctions. These data indicate that a signi®cant proportion of TP53 germline mutations are currently unrecognized. We have carried out detailed studies of the eects of the dierent mutations on splicing, and see distinct variations in the eects of the same mutation in dierent patients. Furthermore we have identi®ed the usage of a nonconsensus splice donor site in four families with an intron 4 splice donor mutation. Oncogene (2001) 20, 2647 ± 2654.
Introduction
Germline TP53 mutations predispose to a variety of malignancies at early ages of onset including breast and brain cancer, bone and soft-tissue sarcomas and adrenocortical carcinomas (Li and Fraumeni, 1969; Li et al., 1988) . There are now almost 200 reports in the literature identifying germline TP53 mutations in families with classic Li-Fraumeni Syndrome (LFS, Li et al., 1988) , in those which are Li-Fraumeni like (Birch et al., 1994a) or have incomplete LF (BrugieÁ res et al., 1993) and also in groups of patients with particular types of tumours or with multiple cancers (for review see Varley et al., 1997a) . Overall the spectrum of mutations seen in the germline is similar to that observed in sporadic tumours, predominantly missense mutations within regions of the gene encoding the central DNA binding domain. To some extent the clustering of mutations within this part of the gene re¯ects a bias in analysis, and it has been estimated that there is under-reporting of mutations within the coding region of the TP53 gene by at least 15 ± 20% (Casey et al., 1996; Varley et al., 1997b) .
Somatic TP53 splicing mutations have been relatively rarely reported, representing under 2% of the database entries (Beroud and Soussi, 1998; HernandezBoussard et al., 1999; http://www.umd.necker.fr:2001 and http://www.iarc.fr/p53/Somatic.htm1.respectively). Furthermore splicing mutations have not been described frequently in the germline (under 3% of reported mutations, see Varley et al., 1997a; Sedlacek et al., 1998; Hernandez-Boussard et al., 1999) . We have previously described germline TP53 splicing mutations in two families (Varley et al., 1997b (Varley et al., , 1998a and we now report a further ®ve splicing mutations. We have carried out detailed studies of the eects of all these mutations.
Results
Of 40 independent germline TP53 mutations identi®ed in families or patients in our studies, seven aected a splice donor (SD) or acceptor (SA) site (Table 1) . Four mutations aected the same residue at the splice donor site in exon 4 (families 69, 2635, 4361 and 2229), three involving identical changes (ACG/g?ACA/g). All four of these mutations are silent (codon 125 Thr?Thr). Two mutations occurred within intron 3, one involving one of the invariant residues at the consensus splice acceptor (ag/TC?aa/TC, family 86), the other a single nucleotide change 11 residues within the intron (tcacc?tcagc, family 4507). The ®nal mutation involved an invariant residue at the consensus splice acceptor site of intron 5 (ag/GT?aa/GT, family 4479). In ®ve families we were able to demonstrate segregation of the mutation with disease. In the two remaining families we were unable to obtain material from additional aected relatives.
The eects on splicing of all these mutations were studied by analysing the transcripts derived from the mutant alleles. This was considered to be important for two main reasons. Firstly as most of the mutations do not aect invariant residues at the splice sites, it was important to demonstrate that they did indeed aect splicing, and were therefore pathogenic mutations. Only with such information can genetic screening and counselling be given with con®dence. Secondly we were interested to see what eects the mutations had on splice site selection, for example was exon skipping the norm, or were cryptic splice sites used as has been described by us in two families (Varley et al., 1998a,b) ?
Mutations affecting the exon 4 splice donor All four mutations aect the same nucleotide (Table 1) . Although some splicing events are common between all four samples (for example the inclusion of intron 4 in the transcript and the use of cryptic sites at positions 12237 and 12099, see Figure 1 ), there are also some dierences. In only two of the four samples was skipping of exon 4 observed and in these two samples there were two dierent nucleotide substitutions. This transcript is predicted to result in a protein product with an in-frame deletion of codons 33 to 125. The use of a cryptic site at position 12691 was also only observed in three of the four samples. Most surprisingly, in all four samples we observed that a nonconsensus splice site within exon 4 was used. This has not been reported previously in TP53. The use of this cryptic non-consensus splice site was ®rst identi®ed by direct sequencing of gel-puri®ed transcripts of abnormal size from family 4631, and was con®rmed by the use of primers designed to be speci®c for this splicing event. We could not detect a transcript of this size in the other samples with an exon 4 splice donor site mutation when the RT ± PCR products were analysed by agarose gel electrophoresis. However when poly(A) + RNA was ampli®ed from these cases using a primer which was speci®c for this splicing event (Ex4int) together with a reverse primer such as Ex5/ 6Rev, we could observe a weak but speci®c band, indicating that this splice site is used very infrequently. We did not observe usage of this splice site in normal control samples. Non-consensus splice sites have been reported, and the one reported here conforms extremely well to the variant GC consensus splice donor sequence identi®ed in a minor proportion of splice sites (for recent review see Mount, 2000) .
Mutations affecting the intron 3 splice acceptor
The details of one family with an intron 3 splice acceptor have been reported previously (family 86 see Varley et al., 1998b) . Brie¯y, in addition to an RT ± PCR fragment of the expected size using primer pairs Ex2/3For and Ex5/6Rev, two additional products were seen, one approximately 20 bp smaller than the expected, and the other approximately 280 bp smaller (Figure 2 ). The smallest fragment corresponded to a product in which there was skipping of exon 4. The transcript which was 20 bp smaller than normal was the result of aberrant splicing between the splice donor of intron 3 and a cryptic splice acceptor site within exon 4. The hypothetical protein product of this transcript would have an in-frame stop codon at the equivalent of position 37, with four novel amino acids at the carboxy terminus.
A sequence variant was detected in genomic DNA from patient 4507 within intron 3. This variant was a c?g transversion 11 bp within the 3' end of intron 3. This sequence change aects the predicted eciency of the intron 3 splice acceptor site as calculated using a splice site prediction program. Not only is the predicted score for the normal splice acceptor site reduced (from 0.64 to 0.37), but the c?g transversion generates a new splice acceptor sequence which has a higher score than the normal one (0.54). In addition recent studies have indicated that when splice acceptor sites contain more than one AG downstream of the branch site, the most 5' is invariably used (Chen et al., 2000) . To investigate whether this mutation did result in the usage of this putative novel splice acceptor upstream of the correct one, a series of RT ± PCR experiments was carried out.
RT ± PCR using a number of primers spanning exons 2 to 6 showed a transcript of the normal size, plus a faint band corresponding in size to a transcript which lacked exon 4. Sequence analysis con®rmed that exon 4 was absent from this transcript ( Figure 3 ).
Splicing speci®c primers were designed to identify products from the predicted novel splice acceptor site ( Table 2 ). The primer Ex3/12011For was designed to amplify transcripts generated from splicing between the normal exon 3 splice donor site and the novel predicted splice acceptor site within intron 3. Such transcripts were identi®ed by RT ± PCR, and sequence analysis con®rmed the splicing pattern. This incorrect splicing would result in the inclusion of 10 nucleotides encoded by intron 3 sequences, and would be predicted to encode a polypeptide of 44 amino acids including a novel 12 amino acids at the carboxy terminus.
The transcript of the normal size was also analysed in detail. This transcript could result from either correct splicing of the wild-type allele or splicing at the normal splice acceptor site of the mutant allele. This question could be resolved utilizing the presence of a codon 72 polymorphism in this patient. The mutant allele was determined to carry the 72Pro variant whereas the wildtype allele carried the 72Arg variant. RT ± PCR ampli®cation of a fragment which included this The family history is indicated as classic LFS, Li-Fraumeni like (Birch et al., 1994a) or not conforming to either of the above, but with a strong family history of cancer (FH). The position of the mutation is shown. SD, splice donor; SA, splice acceptor. Nucleotides within the exon are in capitals, those in the intron are lower case polymorphic site was carried out, followed by analytical restriction digestion using the enzyme BstUI (which will cleave the 72Arg allele but not the 72Pro allele). Digestion con®rmed that there is some splicing of the mutant allele at the normal site, although this transcript appeared to be present as a relatively low proportion of the total (data not shown). It should be noted however that we made no attempt to carry out quantitative PCR. DNA sequence determination of cloned products con®rmed these ®ndings.
There were therefore three products generated from the mutant allele (see Figure 3) . Firstly a product which was spliced normally but which is present at relatively low levels, secondly a product in which exon 4 was skipped, and thirdly a product where exon 3 is spliced to a new splice acceptor site generated by the presence of the mutation within intron 3. This latter transcript would be predicted to produce a truncated protein with an altered Cterminus. Figure 2 Diagram showing the two splicing products detected from cells from patients in family 86 Figure 1 Diagram showing the ®ve dierent splicing products detected in cells from patients with germline TP53 germline exon 4 splice donor mutations (families 69, 2635, 4631 and 2229). The products are described fully in the text. Products A, D and E were detected in cells from all four families. Product C was detected in all except family 2229, product B was detected in families 2635 and 2229 only. Note that product E utilizes a non-consensus splice site within exon 4 A mutation affecting the intron 5 splice acceptor site A mutation was detected at one of the invariant residues of the splice acceptor site in intron 5 (ag/ GT?aa/GT) in family 4479. RT ± PCR could not detect a product representing a transcript in which exon 6 had been skipped, and all transcripts were indistinguishable in size from the normal one. There were two possible explanations for this. Firstly the mutation may not aect splicing. This seems highly unlikely given that the mutation aects one of the invariant residues at the splice acceptor. Secondly the transcript from the mutant allele is very similar in size to the normal one, and cannot be resolved by agarose gel electrophoresis. Screening the sequence around the splice acceptor site of intron 5 of TP53 did reveal other potential cryptic splice sites within 30 bp of the normal splice acceptor. More interestingly, the mutation itself could potentially generate a splice acceptor site that is displaced only one nucleotide 3' of the normal one. Such a transcript would not be detected by RT ± PCR using the primers that we had designed. Three primers were therefore synthesized corresponding to the use of two potential cryptic sites at positions 13291 and 13336, as well as to the`displaced' splice site (see Table  2 ). We could ®nd no evidence for the use of the site at position 13291, but surprisingly both the mutant and control cells showed usage of the site at 13336. It is possible therefore that this site is used infrequently Figure 3 Diagram showing the consequences of an intronic mutation in family 4507. Three products were detected including splicing of the mutant allele at the normal consensus site and skipping of the exon. However the mutation creates a novel splice site which is also used GCTGCTCAGATAGCGATGT Nore. The M13 tail indicated in some primers is to enable direct sequencing of the PCR product. The second group of primers indicated was designed either to span novel splice junctions (novel sequence in bold italics), or to sequence across such junctions even in normal cells. However the primer designed to amplify from a transcript using the`displaced' splice site did detect an RT ± PCR product, indicating that this site is used (see Figure 4) . The putative polypeptide product would have a frameshift at codon 187 introducing a stop codon at position 247, and would therefore have a novel C-terminus of 60 amino acids.
Loss of heterozygosity (LOH)
We were able to obtain tumour material from ®ve malignant and one benign lesion from patients with germline TP53 splicing mutations. Loss of the wildtype allele was seen in all malignant lesions, but not in the benign lesion (benign breast disease). In addition late passage ®broblasts from a patient in family 69 also showed loss of the wild-type allele.
Immunohistochemical detection of p53 expression
We were able to analyse a number of tumour samples plus normal tissue from individuals harbouring germline TP53 splicing mutations. In general the tumours all showed very weak or negative immunostaining, and the normal tissue was negative. This is entirely consistent with other data from this study indicating that the splicing mutations are non-functional (null) mutations.
Functional assays
The yeast functional assay (FASAY) was carried out on cDNA derived from ®broblasts from families 69, 2229 and 2365 (all with an exon 4 SD mutation) and 86 (intron 3 SA mutation). In each case results were obtained that were within the range obtained for wildtype p53 (Table 3) . Fibroblasts from individuals in families 69 and 2635 (exon 4 SD), 86 (intron 3 SA) and 4479 (intron 5 SA) were analysed for their ability to arrest in the G 1 phase of the cell cycle following irradiation (Varley et al., 1998a) . G 1 arrest was normal in ®broblasts from families 86 and 4479, but reduced in the others. Finally, survival experiments following lowdose rate (LDR) irradiation were carried out in cells with an exon 4 SD mutation (families 69 and 2635), an intron 3 SD mutation (family 86) and an intron 5 SA mutation (family 4479). LDR survival was marginally increased in two strains (from families 69 and 4479), but was within the normal range for the other two. These results are all listed in Table 3 .
Discussion
To date we have identi®ed 40 independent germline TP53 mutations (Birch et al., 1994a; Varley et al., 1995 Varley et al., , 1996a Varley et al., ,b, 1997b Varley et al., , 1998a Varley et al., ,b, 1999 . Of these, seven aect splicing (18%), but only two involve the so-called invariant residues at the splice junction (families 86 and 4479). Whilst a clear prediction can be made that these latter mutations will cause aberrant splicing, the consequences of the other germline mutations were uncertain. There is a clinical need to determine the functional consequences of these splice variants. Unless aberrant splicing from the variant allele can be demonstrated these alleles could represent rare polymorphisms rather than mutations, and have no clinical signi®cance. In all cases reported here we were able to demonstrate aberrant splice products. In all cases except one (family 4479, intron 5 SA) we could detect multiple splicing products from the mutant alleles, in some examples up to ®ve dierent products. We found examples of failure to splice an exon resulting in transcription through an intron, of exon skipping, of the generation of a novel splice site and of the use of a variety of dierent cryptic splice sites. Of particular interest with respect to the latter is the use of a non-consensus splice donor sequence in all cases where there is an exon 4 splice donor mutation. The non-consensus sequence matches closely other GC sites (see Mount, 2000 and references therein). The results that we have obtained from studies of the splicing mutations in patients with germline TP53 mutations demonstrate the complexity of splicing, and of the diculty in predicting the precise eects of any particular mutation. However in every case we have examined, we have been able to con®rm that the putative mutation that we have identi®ed does indeed aect splicing.
We carried out some functional studies on cells from patients with germline TP53 splicing mutations. The FASAY, which detects mutant TP53 alleles based on their inability to transactivate target sequences in yeast, failed to detect any of the splicing mutations tested. The consequences of this mutation are that the normal splice site is not used, but a novel one created by the a?g transition is utilized, even though the predicted score is low Some cell strains showed reduced levels of G 1 arrest, or increased survival after low dose-rate irradiation (see Table 3 ), but these changes were not as marked as those which have been reported for cell strains carrying TP53 germline mutations within the core DNA-binding domain (Varley et al., 1998a; Boyle et al., 1999) . These ®ndings can be explained because all the mutations described herein are eectively null mutations rather than missense gain-of-function or dominant-negative mutations. Clearly though the mutations are not functionally silent and are causative of the cancer predisposition in the families described. It is worth noting that the FASAY consistently fails to detect splicing mutations, and therefore the use of this assay as a reliable screen for all types of germline TP53 mutation should be considered with caution. We have previously reported that mutations outside the core DNA-binding domain of TP53 show an overall lower penetrance than missense mutations within the core DNA-binding domain (Birch et al., 1998) . In addition we reported a strong association between loss of the wild-type allele and the type of germline mutation, with LOH being far more frequent in tumours with a loss of function mutation, such as a nonsense or splicing mutation (Varley et al., 1997c; Birch et al., 1998 ). This observation is fully supported by the cases reported in the present study (none of which were included in the previous study) where 5/5 malignant lesions demonstrated loss of the wild-type allele. Immunostaining of normal tissue from individuals from three dierent families with splicing mutations indicated that levels of p53 protein are not elevated in normal tissue. These data tie in well with the functional data described above.
There are four cases of Wilms' tumour in the families with germline TP53 splicing mutations. Recent detailed analysis of the relative frequency and morphology of tumours associated with germline TP53 mutations has shown a signi®cantly elevated frequency of Wilms' tumours in these families (Birch et al. unpublished data) . All cases of Wilms' tumour in our series of 40 families and patients with germline TP53 mutations occurred in families with a germline splicing mutation. At the outset of this study there were only four previous reports of splicing mutations in TP53 (Warneford et al., 1992; Felix et al., 1993; Jolly et al., 1994; Frebourg et al., 1995) other than in our series. None records a case of Wilms' tumour (although Frebourg et al. (1995) do not give details of the families in their study). It remains to be seen whether there is indeed an association between the type of germline TP53 mutation (i.e. splicing) and Wilms tumour as indicated by the present study. In addition to the apparent association between Wilms' tumour and germline TP53 splicing mutations reported here, it is of interest to note that there are three cases of adrenocortical carcinoma in our seven families in addition to three in the literature reports (Warneford et al., 1992; Felix et al., 1993) . Furthermore there is an apparent underrepresentation of rhabdomyosarcomas and soft tissue sarcomas, however the numbers are currently too small to be able to conduct a statistical analysis.
Two of the literature reports aect the splice donor site at exon 4/intron 4 (Warneford et al., 1992; Frebourg et al., 1995) , one is an 11 bp deletion within intron 5 (Felix et al., 1993) and the fourth is a mutation at the intron 5 splice acceptor (Jolly et al., 1994) . The latter aects the same splice site as family 4479 reported in the present study, but Jolly et al. (1994) found only a transcript corresponding to skipping of exon 6, which we did not detect. However in the mutation reported in family 4479, a novel displaced' splice site is created, and this is used exclusively in cells from this patient. No such site is created by the mutation described by Jolly et al., 1994 (ag/GT?cg/GT). Most recently three further splicing mutations have been described in LF families, involving sites in introns 1 and 9 (Verselis et al., 2000) . Interestingly one of the mutations (a splice acceptor mutation in intron 9) is positive in the FASAY, indicating that a protein product is produced which is defective in transactivation. In the cases we have been able to study the FASAY has not detected a mutant product.
In summary, we ®nd that germline TP53 splicing mutations are more frequent than would be estimated from previous literature reports. We have demonstrated that these mutations segregate with cancer predisposition in the families reported here, and that all the mutations aect splicing to varying extents. Analysis of cell lines heterozygous for the mutations indicate that there are minimal eects on some functions of p53 such as the induction of G 1 arrest and longevity, and the mutations are not detected by a yeast functional assay. The evidence is therefore that TP53 splicing mutants are inactive and null.
Materials and methods

TP53 mutation detection
Mutation detection was carried out as described by Varley et al. (1997b) . All exons (coding and non-coding), all splice junctions, the promoter and the 3'-untranslated region were analysed by direct sequencing. Any sequence variants were con®rmed by sequencing the complementary strand. Wherever possible multiple aected individuals from the families were analysed to verify that any putative mutation segregated with the disease. All these studies were carried out with approval of relevant local ethics committees.
Cell culture
Primary human ®broblasts were maintained in Modi®ed Eagle's Medium (MEM, Gibco-BRL) with 15% foetal calf serum (FCS). Human lymphoblastoid cell lines were maintained in RPMI1640 with 15% FCS. All cells were maintained at 378C with 5% CO 2 .
Reverse transcription (RT) ± PCR
Messenger RNA (mRNA) was extracted from human ®broblast or lymphoblastoid cell lines derived from patients with germline TP53 mutations and normal controls using the micro-FastTrack 2.0 mRNA Extraction Kit (Invitrogen). cDNA was synthesized using the Reverse Transcription System (Promega). One microlitre ((l) cDNA was then used in a primary round of Reverse Transcription-PCR (RT ± PCR) using the Expand Long-Range PCR System (Boehringer Mannheim) with the TP53 primers, Ex1For and Ex11Rev, giving a product of 1479 base pairs (bp). Primary PCR products were diluted 1/100 then nested using Taq polymerase (Promega) and the TP53 cDNA speci®c primer combinations, Ex1For and Ex5/6Rev, Ex2/3For and Ex7/ 8Rev, and Ex5/6For and Ex11Rev (Table 2 ). These primer combinations gave overlapping products of 760 bp, 765 bp and 760 bp respectively (sizes including M13 tails for sequencing). RT ± PCR products were separated on 2% agarose gels to detect aberrantly sized transcripts. Some primers were synthesized corresponding to transcripts generated by the use of alternate or cryptic splice sites. These were used in combination with those listed above as appropriate (see Table 2 ). The eciency of splice donor and acceptor sites was estimated using a splice site prediction program (http://www.fruit¯y.org/seq_tools/splice.html). or by using calculations described by Shapiro and Senapathy (1987) .
Loss of heterozygosity
Loss of heterozygosity in tumours from patients with germline splicing mutations was determined by direct sequencing or by restriction digest as previously described (Varley et al., 1997c) .
Functional analysis of mutant p53
A number of assays were used to determine the eects of the splicing mutations on p53 function including the yeast transactivation assay, G 1 arrest and low dose rate survival measurements as described previously (Boyle et al., 1997 (Boyle et al., , 1999 Varley et al., 1998a) .
Immunohistochemistry
Immunohistochemical detection of p53 protein was carried out using the CM1 antibody (Bartek et al., 1991; Midgley et al., 1992) on sections from ®xed and embedded material as previously described (Birch et al., 1994b) . The extent of the staining was assessed and expressed as the percentage of cells staining and with respect to the intensity of staining within those cells (7, +, ++ or +++; negative, weak, moderate or strong nuclear staining respectively). Negative and positive controls were processed at the same time, and are as described and shown previously (Birch et al., 1994b) .
